Fig. 1.

Treatments with cAM-MSCs effectively reduced the symptoms of the experimental DNCB-induced atopic dermatitis mouse model on Days 28 and 56. (A) Scheme of the experimental atopic dermatitis mouse model, including the time point at which DNCB was administered. (B) Representative images of AD mice on Days 14, 28, 42 and 56 after treatment with cAM-MSCs (MSCs); negative control (CTL); pimecrolimus (Pime); and PBS control (PBS). (C) Scoring of scarring and dryness signs for CTL, PBS, MSCs and Pime on Day 56 (none, 0; mild, 1; moderate, 2; and severe, 3). n = 4 in each group; mean ± SD; * p < 0.05, *** p < 0.001, n.s. not significantly different versus the control. (D) Scoring of dermatologic signs for DNCB-induced mice in each group on Day 56 n = 4; mean ± SD, * p < 0.05, ** p < 0.01, *** p < 0.001. (E) Body weights of atopic dermatitis mouse model in each group on Day 14 and Day 56; n = 4; mean ± SD, * p < 0.05, ** p < 0.01 n.s. not significantly different versus the control